Tag: Ted

In 2020, Tepezza (teprotumumab-trbw) made history as the first medication specifically approved by the FDA for the treatment of Thyroid Eye Disease (TED). This groundbreaking medication is not a small-molecule drug like many traditional treatments but is, in fact, a fully human monoclonal antibody. It works by targeting the underlying cause of the disease rather than just managing the symptoms.

In 2020, the FDA approved Tepezza as the first and only medication to address the underlying cause of Thyroid Eye Disease (TED), rather than just managing symptoms. But **what type of medication is Tepezza**? It is a targeted biologic known as a monoclonal antibody that has revolutionized the treatment landscape for this autoimmune condition.

In 2020, the FDA approved Teprotumumab (brand name Tepezza), the first drug specifically developed to treat Thyroid Eye Disease (TED), marking a major shift from previous symptom-focused therapies. This medication, known as a TED drug, targets the underlying autoimmune mechanism responsible for the debilitating eye condition.